FGF19 action in the brain induces insulin-independent glucose lowering.

Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, Bergman RN, Wasserman DH, Schwartz MW
J Clin Invest. 2013 123 (11): 4799-808

PMID: 24084738 · PMCID: PMC3809800 · DOI:10.1172/JCI70710

Insulin-independent glucose disposal (referred to as glucose effectiveness [GE]) is crucial for glucose homeostasis and, until recently, was thought to be invariable. However, GE is reduced in type 2 diabetes and markedly decreased in leptin-deficient ob/ob mice. Strategies aimed at increasing GE should therefore be capable of improving glucose tolerance in these animals. The gut-derived hormone FGF19 has previously been shown to exert potent antidiabetic effects in ob/ob mice. In ob/ob mice, we found that systemic FGF19 administration improved glucose tolerance through its action in the brain and that a single, low-dose i.c.v. injection of FGF19 dramatically improved glucose intolerance within 2 hours. Minimal model analysis of glucose and insulin data obtained during a frequently sampled i.v. glucose tolerance test showed that the antidiabetic effect of i.c.v. FGF19 was solely due to increased GE and not to changes of either insulin secretion or insulin sensitivity. The mechanism underlying this effect appears to involve increased metabolism of glucose to lactate. Together, these findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the brain’s capacity to rapidly, potently, and selectively increase insulin-independent glucose disposal.

MeSH Terms (16)

Animals Brain Diabetes Mellitus, Type 2 Fibroblast Growth Factors Glucose Glucose Tolerance Test Injections, Intraventricular Insulin Male Mice Mice, Inbred C57BL Mice, Obese Mice, Transgenic Models, Biological Pro-Opiomelanocortin Signal Transduction

Connections (4)

This publication is referenced by other Labnodes entities: